Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC

NCT03347292 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Regorafenib(Stivarga, BAY73-4506)
DRUG: Pembrolizumab

Sponsor

Bayer

Collaborators

[object Object]